Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

Web: lktlabs.com

## **Product Information**

Product ID 07332 CAS No. 936890-98-1

**Chemical Name** 

Synonym

Formula C<sub>21</sub>H<sub>22</sub>N<sub>6</sub>O<sub>3</sub> Formula Wt. 406.44

**Melting Point** 

Purity ≥99%

Solubility DMSO 18 mg/mL (44.28 mM)

Water Insoluble Ethanol Insoluble

Store Temp 4°C Ship Temp Ambient

Description OSI-027 is an inhibitor of mTORC1/2 that exhibits anticancer chemotherapeutic activity. In vitro, OSI0027 inhibits

phosphorylation of downstream target Akt, inhibiting cell proliferation in breast cancer cells. OSI-027 also induces apoptosis in several lymphoid cell lines including mantle cell lymphoma, acute lymphocytic leukemia (ALL), and others. In animal models of

cancer, this compound inhibits tumor growth.

## **Pricing and Availability**

## Bulk quanitites available upon request

Product ID	Size	List Price
O7332	1 mg	\$74.40
O7332	5 mg	\$190.10
O7332	10 mg	\$322.30

References Li H, Lin J, Wang X, et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1057-66. PMID: 22476852.

> Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Pumadependent apoptosis in lymphoid malignancies. Blood. 2012 Jan 12;119(2):476-87. PMID: 22080480.

> Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011 Mar 1;71(5):1573-83. PMID: 21363918.

Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy. 2010 Oct;6(7):966-7. PMID: 20699667.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.